ZKLJ02
/ KumMing Longjin Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 11, 2026
ZKLJ02-I: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZKLJ02 Injection in Healthy Chinese Research Participants
(clinicaltrials.gov)
- P1 | N=50 | Completed | Sponsor: Yunnan Zhongke Longjin Biotechnology Co.,Ltd.
New P1 trial
January 31, 2026
A randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous administration of ZKLJ02 injection in healthy Chinese research participants
(ChiCTR)
- P=N/A | N=50 | Recruiting | Sponsor: Bishan People's Hospital of Chongqing; Yunnan Zhongke Longjin Biotechnology Co.,Ltd.
New trial • Cardiovascular • Ischemic stroke
1 to 2
Of
2
Go to page
1